Last reviewed · How we verify
NCT03284190: SMASH
Scandinavian Multicentre Acute Subdural Hematoma (SMASH) Study
trial testing Surgery in Acute Subdural Hematoma in 1,600 participants. Status unknown.
1 October 2018
Quick facts
| Lead sponsor | Karolinska University Hospital |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 1,600 |
| Start date | 6 March 2018 |
| Primary completion | 1 October 2018 |
| Estimated completion | 1 December 2018 |
Drugs / interventions tested
- Surgery
Conditions studied
- Acute Subdural Hematoma — all drugs for Acute Subdural Hematoma →
Sponsor
Karolinska University Hospital
Who can join
Eligibility, any sex, with Acute Subdural Hematoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
In a multi-national population-based cohort, the investigators want to compare the clinical course and clinical outcome of elderly patients (≥70 y/o) compared with younger patients (\< 70 y/o) with acute subdural hematoma treated surgically. An improved understanding of the clinical outcome and the prognostic factors of acute subdural hematomas would allow physicians to make better decisions about treatment options in traumatic ASDH in the elderly population.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Scandinavian Multicenter Acute Subdural Hematoma (SMASH) Study: Study Protocol for a Multinational Population-Based Consecutive Cohort.
Bartek J, Laugesen C, Mirza S, Forsse A, et al · · 2019 · cited 4× · PMID 29762769 · DOI 10.1093/neuros/nyy173
Verify or expand the search:
- PubMed search for NCT03284190
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Surgery
Trials testing the same drug.
- NCT07472478 — Phase II Neoadjuvant Study of Garsorasib Followed by Ivonescimab Plus Chemotherapy in Resectable Stage IIA-IIIB KRAS G12 · Phase 2 · not yet recruiting
- NCT07524452 — Becotatug Vedotin (MRG003) in Combination With PD-1 Inhibitor Versus PD-1 Inhibitor for the Treatment of EGFR-positive, · Phase 3 · recruiting
- NCT07053033 — Laser Interstitial Thermal Therapy (LITT) or Surgery and Adjuvant Reirradiation for Recurrent Brain Metastases (LaSAR Be · Phase 2 · recruiting
- NCT07352007 — Sintilimab Combined With Stereotactic Body Radiotherapy as Neoadjuvant Therapy for Resectable Hepatocellular · Phase 2 · not yet recruiting
- NCT07419932 — Response to Neoadjuvant Treatment in Locally Advanced Thyroid Cancer · recruiting
Other Karolinska University Hospital trials
Trials by the same sponsor.
- NCT07424690 — Catheter Ablation vs Conservative Care in Elderly Patients With Atrial Fibrillation · NA · not yet recruiting
- NCT06639191 — [177Lu]Lu-AKIR001 First-in-human Study · EARLY_PHASE1 · recruiting
- NCT03629977 — Timing of Renal Replacement Therapy in the Critically Ill Patients · recruiting
- NCT06983197 — Iatrogenic Deficiencies in ICU Patients With Prolonged Continuous Renal Replacement Therapy · not yet recruiting
- NCT06835816 — Amino Acid Supplementation in Continuous Renal Replacement Therapy · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03284190 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Karolinska University Hospital
- Last refreshed: 6 March 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03284190.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing